Caricamento...

Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials

Although parenteral therapy with glycoprotein (GP) IIb/IIIa inhibitors has resulted in a reduced risk of death or myocardial infarction in patients with acute coronary syndromes and in patients undergoing percutaneous coronary intervention, the benefit is achieved only during the infusion period. Or...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cardiol
Autore principale: Cannon, Christopher P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wiley Periodicals, Inc. 2009
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6654967/
https://ncbi.nlm.nih.gov/pubmed/11129681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960231105
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !